Cagrilintide Research for Obesity
An evidence-based overview of research examining Cagrilintide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Cagrilintide has shown significant weight loss efficacy in clinical trials. Phase 2 monotherapy achieved -10.8% weight loss at 26 weeks. When combined with semaglutide (CagriSema), Phase 1b/2 data showed -15.6% to -17.1% weight loss. The Phase 3 REDEFINE 1 trial reported -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cagrilintide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.